1,348 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
ONCE Spark Therapeutics, Inc. $57.05 $2.14B N/A
Article Searches
Spark Therapeutics Hopes to Cure a Rare Blindness for $850,000 a Pop http://www.zacks.com/stock/news/287703/spark-therapeutics-hopes-to-cure-a-rare-blindness-for-%24850000-a-pop?cid=CS-ZC-FT-287703 Jan 03, 2018 - Small biotech firm Spark Therapeutics (ONCE) recently announced a new gene therapy that is designed to treat a rare, inherited retinal disease that can cause blindness. Approved by the FDA, Luxturna costs $425,000 per eye, or $850,000 for both
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer http://www.zacks.com/stock/news/287723/biotech-stock-roundup-gwph-submits-epidiolex-in-the-eu-sangamo-inks-deal-with-pfizer?cid=CS-ZC-FT-287723 Jan 04, 2018 - Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Intel Security Flaw, Spark Therapeutics, & Tech Buyout Rumors http://www.zacks.com/stock/news/287988/intel-security-flaw-spark-therapeutics-tech-buyout-rumors?cid=CS-ZC-FT-287988 Jan 05, 2018 - On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including the major security flaw found in Intel processors, a cure for a rare blindness discovered by a young biotech firm, and several huge tech industry M&A rumors.
Painkiller that once cost $138 is now $2,979 http://rss.cnn.com/~r/rss/money_topstories/~3/NjA70HRMfbU/index.html Feb 15, 2018 - Read full story for latest details.
Will This Trend Sucker In Retailers Once More? https://www.fool.com/investing/2018/02/15/will-this-trend-sucker-in-retailers-once-more.aspx?source=iedfolrf0000001 Feb 15, 2018 - Supposedly the burned hand learns best, but some retailers are willing to risk getting singed again.
Painkiller that once cost $138 is now $2,979 http://rss.cnn.com/~r/rss/money_markets/~3/olvGftARya4/index.html Feb 15, 2018 - Read full story for latest details.
Polished Rancho Mirage home was once part of President Gerald Ford's estate http://www.latimes.com/business/realestate/hot-property/la-fi-hotprop-gerald-ford-estate-20180213-story.html Feb 13, 2018 -

A desert home with ties to both Hollywood and the White House has listed for sale in Rancho Mirage at $3.695 million.

Set in the Thunderbird Country Club, the contemporary house was built in 2016 on what was once part of former President Gerald Ford and Betty Ford’s estate. The previous house,...

Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus http://www.zacks.com/stock/news/299142/gene-therapy-in-limelight-on-novartis-deal-3-stocks-in-focus?cid=CS-ZC-FT-299142 Apr 13, 2018 - With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug http://www.zacks.com/stock/news/299193/pfizer-starts-phase-ib-for-duchenne-muscular-dystrophy-drug?cid=CS-ZC-FT-299193 Apr 13, 2018 - Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates http://www.zacks.com/stock/news/302954/jazz-pharmaceuticals-jazz-q1-earnings-sales-top-estimates?cid=CS-ZC-FT-302954 May 09, 2018 - Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.

Pages: 1...128129130131132133134135

<<<Page 133>